Active — Not RecruitingPhase 1

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Thailand147 participantsStarted 2022-07-01

Plain-language summary

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * post AKI stage 2-3 * CrCl \> 20 Exclusion Criteria: * pregnancy * post kidney transplant * previous use of SGLT2 Inhibitors * history of ketoacidosis

What they're measuring

MAKE365

Timeframe: 1 year

Trial details

NCT IDNCT05360615

SponsorChulalongkorn University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Empagliflozin in Post AKI Stage 2-3 trials